ArticleRheumatology and therapy2026

Cost-per-Responder Analysis of Bimekizumab (IL-17A/F Inhibitor) Against IL-Inhibitors for Psoriatic Arthritis in Spain, Based on Matching-Adjusted Indirect Comparisons.

Jorge Mestre-Ferrandiz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.